<DOC>
	<DOC>NCT01662999</DOC>
	<brief_summary>The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together</brief_summary>
	<brief_title>Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Healthy subjects as determined by no clinically significant deviation from normal in medical history, Physical Examination, vital signs, 12lead ECG, and clinical laboratory determinations Body mass index (BMI) of 18 to 30 kg/m2 Men and women, ages 18 to 45 years Women of childbearing potential must use acceptable methods of highly effective birth control History of chronic or recurrent urinary tract infection for females History of allergies or adverse reactions to Dipeptidyl peptidaseIV (DPP4) or Sodiumglucose transporter type 2 (SGLT2) inhibitors Any significant acute or chronic medical illness Current or recent gastrointestinal disease Any major surgery within 4 weeks of study drug administration Prior exposure to saxagliptin or dapagliflozin or related drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>